90 related articles for article (PubMed ID: 14604577)
1. The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
Donners H; Vermoesen T; Willems B; Davis D; van der Groen G
Vaccine; 2003 Dec; 22(1):104-11. PubMed ID: 14604577
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.
Davis D; Donners H; Willems B; Lövgren-Bengtsson K; Akerblom L; Vanham G; Barnett S; Morein B; Heeney JL; van der Groen G
Vaccine; 2004 Jan; 22(5-6):747-54. PubMed ID: 14741168
[TBL] [Abstract][Full Text] [Related]
3. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.
Zolla-Pazner S; Xu S; Burda S; Duliege AM; Excler JL; Clements-Mann ML
J Infect Dis; 1998 Nov; 178(5):1502-6. PubMed ID: 9780275
[TBL] [Abstract][Full Text] [Related]
5. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
[TBL] [Abstract][Full Text] [Related]
6. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
7. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
8. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
Zolla-Pazner S; Alving C; Belshe R; Berman P; Burda S; Chigurupati P; Clements ML; Duliege AM; Excler JL; Hioe C; Kahn J; McElrath MJ; Sharpe S; Sinangil F; Steimer K; Walker MC; Wassef N; Xu S
J Infect Dis; 1997 Apr; 175(4):764-74. PubMed ID: 9086128
[TBL] [Abstract][Full Text] [Related]
10. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
11. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
Devico A; Silver A; Thronton AM; Sarngadharan MG; Pal R
Virology; 1996 Apr; 218(1):258-63. PubMed ID: 8615032
[TBL] [Abstract][Full Text] [Related]
12. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
[TBL] [Abstract][Full Text] [Related]
13. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
14. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
15. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates.
Davis D
Vaccine; 1996 Mar; 14(4):353-4. PubMed ID: 8744564
[No Abstract] [Full Text] [Related]
17. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
18. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
19. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
20. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]